FACILITY: [REDACTED]
DATE: [REDACTED]
CASE: #E2756895
ATTENDING: [REDACTED]
UNIT: WARD 92
OBJECTIVE: Behavioral Compliance Induction
SUBJECT #1138-B7 was brought to the operating theater, prepped and draped in the usual fashion. Intravenous access was established using a 20-gauge catheter inserted into the left antecubital vein. Electrodes were placed on the scalp for continuous EEG monitoring. Additional sensors were attached to record heart rate, respiratory rate, and galvanic skin response (GSR).
Subject presents as a 25 year old male, physically healthy, baseline vitals recorded WNL. Subject exhibited signs of anxiety and resistance, which were managed by the use of sedatives (2 mg Midazolam IV).
[09:53:11]: Subject questioned to establish baseline cognitive and physiological parameters. Orientation, recall, and basic comprehension intact.
[10:00:00]: Infusion of proprietary psychotropic agent PCA-35 initiated at a rate of 5 mL/min.
[10:03:48]: Subject displays signs of restlessness. Cortical activation indicated by increased uptake on EEG. Subject gives responses to verbal stimuli and reports a sensation of lightheadedness.
[10:04:25]: Subject complains of stinging sensation and bittersweet taste. Noted slight tremor in extremities and increased heart rate. GSR indicates heightened anxiety.
[10:05:13]: Subject questioned to establish cognitive and physiological parameters. Noted delayed responses. Subject struggles to follow simple instructions, becomes distracted, provides incoherent explanations of surroundings, misinterprets questions.
[10:09:32]: Subject begins to exhibit signs of altered perception, including auditory hallucinations and delirium. EEG shows increased theta wave activity. Physical agitation observed; restraints effective in maintaining Subject's position. Subject too agitated for cognitive and physiological testing.
[10:14:45]: Administration of compound #GS-P5R initiated at 12 L/min via inhalation mask to reduce anxiety and stabilize neural response. Infusion of PCA-35 increased to 7.5 mL/min.
[10:19:48]: Subject's responses to verbal and physical stimuli decrease significantly. Continued monitoring shows stable vitals but increased physical rigidity. Administered 1 mg Lorazepam IV to reduce muscle tension.
[10:24:22]: Subject’s speech becomes slurred and incoherent. Noted disorientation to stimuli, increased muscle laxity. Decrease in heart rate and blood pressure.
[10:33:14]: Subject enters a semi-catatonic state. Eyes remain open but unresponsive to visual stimuli. Pupils equal but dilated. EEG shows dominant delta wave activity.
[10:42:28]: Subject displays signs of decreased neural responsiveness. Decreased pupillary reaction, continued slow rolling movement of the eyes, jerky movement of the whole body (hypnic jerks). Persistent drooling noted.
[10:45:04]: Infusion of PCA-13 reduced to 1 mL/min. Administration of compound #GS-P5R reduced to 2 L/min via nasal cannula.
[10:50:34]: Subject engaged with repetitive commands in accordance to Behavioral Compliance Protocols. Verbal cues, electronic conditioning, and multi-sensory stimuli reinforcement prove ineffective. Subject remains largely non-reactive.
[10:57:55]: Subject’s eyes remain unfocused with significant drooping. Attempts to direct gaze result in brief eye opening, followed by rapid drooping. Subject mumbles incoherently.
[10:58:06]: Speculum applied to maintain eyelid retraction for continuous observation and responsiveness testing. Subject demonstrates minimal resistance; remains in stuporous state. Droplets of propriety psychotic #3A administered to each eye. Immediate increase in pupil dilation and noticeable twitching observed.
[11:00:17]: Visual stimulus presented. Subject's eyes remain fixed and extremely dilated. Noted tremors in hands, erratic breathing patterns, increase in heart rate. Subject occasionally mumbles with extreme delay in response latency to verbal and physical testing.
[11:05:23]: Subject engaged with repetitive commands in accordance to Behavioral Compliance Protocols. Verbal cues, electronic conditioning, and multi-sensory stimuli reinforcement prove insignificant. Subject displays significant cognitive impairment, involuntary reflexes, significant drooling, and uncoordinated movements.
[11:10:19]: Increased auditory and visual stimuli introduced to enhance command comprehension of Behavioral Compliance Protocols. Subject displays signs of severe neural suppression. EEG findings variable and nonspecific, low voltage and slow irregular activity nonreactive to sensory stimuli.
[11:15:52]: Subject engaged with high-intensity visual stimuli (rapid flashing) and continuous auditory commands. Subject shows brief eye fixation on visual stimulus, with occasional facial twitching. Overall response is characterized by slow, inconsistent movements and frequent confusion. Subject’s attempts to respond are sporadic, sluggish, and incoherent.
[11:20:14]: Administered low-frequency auditory tones and ambient lighting. Subject displays intermittent eye tracking and reflexive vocalizations. Eyes lubricated to prevent irritation; speculum remains in place. Despite the high level of impairment, occasional partial compliance with commands noted.
[11:30:31]: Subject provided with 500 mL saline IV to maintain hydration. Subject engaged with repetitive commands in accordance to Compliance Protocols. Verbal cues, electronic conditioning, and multi-sensory stimuli reinforcement prove moderately effective as demonstrated by increased uptake seen on EEG. Noted severe motor function impairment, persistent drooling, disorientation.
[11:37:48]: Visual and auditory stimuli calibrated to induce deep trance state in preparation for Hypnotic Compliance Protocols. Subject's head and neck stabilized to ensure alignment with visual stimuli. Monitored vital signs remain stable but indicate persistent sedation effects. Subject remains largely unresponsive, exhibiting only involuntary reflexes and intense eye fixation on visual stimulus.
[12:00:00]: End of Behavioral Compliance Induction log. Subject's transition to hypnotic phase officially logged and observed.
TRANSFER OF CARE: [REDACTED]
